APRE
Aprea Therapeutics, Inc.
4.06
USD
This page is just a preview of the data found in TrendSpider’s full version
Aprea Therapeutics, Inc. stock is down -1.22% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 December’s closed higher than November.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246, a small molecule p53 reactivator, which is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia (AML)
